Picture of Zymeworks logo

ZYME — Zymeworks Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-13.34%
3m-0.35%
6m-57.62%
1yr-83.09%
Volume Change (%)
10d/3m-24.38%
Price vs... (%)
52w High-85.66%
50d MA-7.08%
200d MA-57.52%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-69.54%
Return on Equity-72.74%
Operating Margin-870.72%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for ZYME

Will the Zymeworks Inc share price run continue? background image

Will the Zymeworks Inc share price run continue?

In this article we will quickly re-cap the broker forecasts for Zymeworks Inc (NYQ:ZYME). The Zymeworks Inc share price has risen by 1.85% over the past month and it’s currently trading at 32.52. For investors considering whether to bu...

Upbeat broker recommendations for Zymeworks Inc background image

Upbeat broker recommendations for Zymeworks Inc

The Zymeworks Inc (NYQ:ZYME) share price has risen by 1.88% over the past month and it’s currently trading at 37.38. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will cont...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Zymeworks EPS forecast chart

Profile Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
May 2nd, 2017
Public Since
April 28th, 2017
No. of Shareholders
26
No. of Employees
327
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
57,771,204

ZYME Share Price Performance

Upcoming Events for ZYME

Q2 2022 Zymeworks Inc Earnings Release

Q3 2022 Zymeworks Inc Earnings Release

Similar to ZYME

Picture of ADC Therapeutics SA logo

ADC Therapeutics SA

us flag iconNew York Stock Exchange

Picture of Ambrx Biopharma logo

Ambrx Biopharma

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

Picture of Arcus Biosciences logo

Arcus Biosciences

us flag iconNew York Stock Exchange

Picture of Biohaven Pharmaceutical Holding logo

Biohaven Pharmaceutical Holding

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email